Table 4 Summary of results of the Monte Carlo simulation for the Rett syndrome case using a discount rate of \(r=13\%\)
From: Financing repurposed drugs for rare diseases: a case study of Unravel Biosciences
| Â | Â | Monte Carlo simulation | ||
|---|---|---|---|---|
| Â | Â Expected rNPV after each phase | Average rNPV | Standard deviation of rNPV | Upper bound on the rNPV |
Discovery, preclinical development, and phase 1 | 32.3 | 23.19 | 21.45 | 123.98 |
Phase 2 | 117.1 | 105.07 | 48.10 | 325.33 |
Phase 3 | 292.3 | 288.37 | 80.15 | 687.25 |
FDA submission-to-launch | 406.5 | 401.78 | 96.35 | 881.26 |
Overall | 14.2 | 8.79 | 12.81 | 69.20 |